An investor account points followers to its latest weekly recap of $NVO, $LLY and the wider obesity market. Details are in the linked roundup.
Recap by typeshit. Post by Investseekers on X.
At the SIO congress in Palermo, specialists flagged short real-world adherence and no national reimbursement in Italy. Oral semaglutide and orforglipron are expected there in 2027.
11:54
Ryan Sims of Optimal Health Project gives a follow-up on how things have gone in the months since his 35-pound loss on the experimental drug.
The Tico Times reports Costa Rica's public system is considering offering GLP-1 weight loss drugs to patients. Tap through for where the discussion stands.
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
A short personal check-in from a creator who tags her post with tirzepatide. No numbers or details beyond the update itself.
Presented at EASD in Milan, the shot kills fat cells instead of shrinking them. UAB's Timothy Garvey calls the early results remarkable, though not yet peer reviewed.
Loading…